The funny thing with Medistem is when you look at the history, long term shareholders were pissed it sold for just $26 million, receiving only about $1.35 per share (0.27 cash + 1.08 stock that lost value) when it was trading $2 - $3 earlier causing many people a loss who believed it was undervalued. To be fair, Tim Dixon was not involved with that company, not that I know of, but some of the scientists are on the advisory board, in addition to Dr Ichim as director who also held a CEO position in that other company. It didn't sound like a good deal so why do people occasionally mention this acquisition? Let's hope the same does not happen with TSOI. Am I missing something?
News 
Market Data 
Discover 
